Literature DB >> 15541961

Biomarkers of ovarian tumours.

Amy V Rapkiewicz1, Virginia Espina, Emanuel F Petricoin, Lance A Liotta.   

Abstract

Ovarian cancer is one of the most aggressive gynaecological malignancies and most often the high mortality is a direct result of delays in diagnosis. The development of an ovarian cancer-specific biomarker for the early detection of disease has the capacity to improve the dismal survival rate. Currently, there are multiple investigations that are utilising both genomic and proteomic technologies to identify genes, gene products and proteins that may potentially identify diagnostic ovarian cancer biomarkers. Here, we review the studies that are involved in biomarker development for the detection of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541961     DOI: 10.1016/j.ejca.2004.05.021

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

Review 1.  Contemporary progress in ovarian cancer screening.

Authors:  Christine S Walsh; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

Review 2.  Molecular signatures of ovarian cancer: from detection to prognosis.

Authors:  Christine S Walsh; Beth Y Karlan
Journal:  Mol Diagn Ther       Date:  2010-02-01       Impact factor: 4.074

3.  Acacetin inhibits VEGF expression, tumor angiogenesis and growth through AKT/HIF-1α pathway.

Authors:  Ling-Zhi Liu; Yi Jing; Lisa L Jiang; Xiu-E Jiang; Yue Jiang; Yongyut Rojanasakul; Bing-Hua Jiang
Journal:  Biochem Biophys Res Commun       Date:  2011-08-27       Impact factor: 3.575

4.  Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin.

Authors:  Siti S Abdullah-Soheimi; Boon-Kiong Lim; Onn H Hashim; Adawiyah S Shuib
Journal:  Proteome Sci       Date:  2010-11-17       Impact factor: 2.480

5.  Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.

Authors:  Jongyun Hwang; Sunghun Na; Hyangah Lee; Dongheon Lee
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

6.  Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer.

Authors:  Timucin Mermer; Mustafa Cosan Terek; Burak Zeybek; Ahmet Mete Ergenoglu; Ahmet Ozgur Yeniel; Aydın Ozsaran; Osman Zekioglu
Journal:  J Gynecol Oncol       Date:  2012-04-03       Impact factor: 4.401

7.  A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Authors:  V A Heinzelmann-Schwarz; M Gardiner-Garden; S M Henshall; J P Scurry; R A Scolyer; A N Smith; A Bali; P Vanden Bergh; S Baron-Hay; C Scott; D Fink; N F Hacker; R L Sutherland; P M O'Brien
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

8.  Identification of new genes associated to senescent and tumorigenic phenotypes in mesenchymal stem cells.

Authors:  Joana Cristina Medeiros Tavares Marques; Déborah Afonso Cornélio; Vivian Nogueira Silbiger; André Ducati Luchessi; Sandro de Souza; Silvia Regina Batistuzzo de Medeiros
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

9.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

10.  Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients.

Authors:  Bih-Rong Wei; Shelley B Hoover; Mark M Ross; Weidong Zhou; Francesco Meani; Jennifer B Edwards; Elizabeth I Spehalski; John I Risinger; W Gregory Alvord; Octavio A Quiñones; Claudio Belluco; Luca Martella; Elio Campagnutta; Antonella Ravaggi; Ren-Ming Dai; Paul K Goldsmith; Kevin D Woolard; Sergio Pecorelli; Lance A Liotta; Emanuel F Petricoin; R Mark Simpson
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.